Enlivex Therapeutics
1.01
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Enlivex Therapeutics
Enlivex Therapeutics Ltd. opera como una compañía de inmunoterapia de reprogramación de macrófagos en etapa clínica. Está desarrollando Allocetra, una terapia basada en células para tratar la disfunción e insuficiencia orgánica asociada con la sepsis que se encuentra en fase II de ensayo clínico, así como en ensayo preclínico para tratar tumores sólidos. Enlivex Therapeutics Ltd. fue fundada en 2005 y tiene su sede en Nes Ziona, Israel.
Trade GPT
Similar Stocks
© 2025 Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.
Rockalpha Limited, operates from its Singapore headquarters at CapitaSky 808, 79 Robinson Road, Singapore 068897, with a regional office at Level 6, Core C, Cyberport 3, 100 Cyberport Road, Hong Kong.